NCT03981276 Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
| NCT ID | NCT03981276 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Rebecca Schule |
| Condition | Hereditary Spastic Paraplegia |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-10-14 |
| Primary Completion | 2039-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-10-14 with a primary completion date of 2039-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine the clinical spectrum and natural progression of Hereditary Spastic Paraplegias (HSP) and related disorders in a prospective multicenter natural history study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the genetic etiology and molecular mechanisms of these diseases.
Eligibility Criteria
Inclusion criteria: * One of the following: 1. Primary participant: Clinical or genetic diagnosis of HSP or a related disorder 2. Secondary participant: Unaffected family member (1st or 2nd degree relative) of primary participant (with the above-mentioned restrictions for special populations) able to give informed consent 3. Unrelated healthy control able to give informed consent AND * Written informed consent AND \- Participants are willing and able to comply with study procedures Exclusion criteria: * Missing informed consent of primary or secondary participant/ healthy control/ legal representatives * For controls: evidence of a neurodegenerative disease or movement disorders; inability to give informed consent
Contact & Investigator
Rebecca Schüle, PD Dr.
PRINCIPAL INVESTIGATOR
University Hospital Tuebingen
Frequently Asked Questions
Who can join the NCT03981276 clinical trial?
This trial is open to participants of all sexes, studying Hereditary Spastic Paraplegia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03981276 currently recruiting?
Yes, NCT03981276 is actively recruiting participants. Contact the research team at rebecca.schuele-freyer@uni-tuebingen.de for enrollment information.
Where is the NCT03981276 trial being conducted?
This trial is being conducted at Innsbruck, Austria, Bonn, Germany, Erlangen, Germany, Essen, Germany and 9 additional locations.
Who is sponsoring the NCT03981276 clinical trial?
NCT03981276 is sponsored by Dr. Rebecca Schule. The principal investigator is Rebecca Schüle, PD Dr. at University Hospital Tuebingen. The trial plans to enroll 2,000 participants.